AZN vs CHRS
AZN: AstraZeneca is a global, science-led biopharmaceutical company focused on transforming patient outcomes in oncology, rare diseases, and chronic conditions through a robust and diverse R&D pipeline. CHRS: A specialized immuno-oncology company driving growth through its FDA-approved PD-1 inhibitor LOQTORZI and a clinical-stage pipeline targeting immune resistance in solid tumors.
Side-by-side fundamentals
| Metric | AZN | CHRS | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $168.82 | $1.00 | |
| Market cap | $254.2B | $155M | |
| Net margin FY2025, SEC XBRL | +17.4% | n/a | |
| Gross margin FY2025, SEC XBRL | +81.9% | n/a | |
| Operating margin FY2025, SEC XBRL | +23.4% | n/a | |
| ROE FY2025, SEC XBRL | +21.0% | +275.4% | CHRS higher |
| ROA FY2025, SEC XBRL | +9.0% | +65.0% | CHRS higher |
| Revenue growth (YoY) FY2025, SEC XBRL | +8.6% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +9.8% | n/a | |
| Dividend yield as of 2026-09-03 | +2.6% | n/a | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-09-03 | 0.34 | 1.50 | |
| 1-year return as of 2026-10-20 close | +0.6% | -44.1% | AZN higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.